X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with Prime Securities - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs PRIME SECURITIES - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

PRIME SECURITIES 
   Change

Prime Securities is promoted by the Sheths which is also the controlling family of Great Eastern Shippng Company. The company offers financial services in the field of corporate finance, capital markets advisory, and broking. The company also establi... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES PRIME SECURITIES INDOCO REMEDIES/
PRIME SECURITIES
 
P/E (TTM) x 31.7 6.3 500.5% View Chart
P/BV x 3.8 229.8 1.6% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 INDOCO REMEDIES   PRIME SECURITIES
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
PRIME SECURITIES
Sep-13
INDOCO REMEDIES/
PRIME SECURITIES
5-Yr Chart
Click to enlarge
High Rs36015 2,371.1%   
Low Rs2492 12,455.0%   
Sales per share (Unadj.) Rs119.0-12.1 -979.9%  
Earnings per share (Unadj.) Rs8.4-32.8 -25.5%  
Cash flow per share (Unadj.) Rs15.2-32.5 -46.9%  
Dividends per share (Unadj.) Rs1.600-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs70.70.2 30,681.5%  
Shares outstanding (eoy) m92.1526.47 348.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.6-0.7 -361.6%   
Avg P/E ratio x36.4-0.3 -13,879.4%  
P/CF ratio (eoy) x20.0-0.3 -7,560.9%  
Price / Book Value ratio x4.337.3 11.5%  
Dividend payout %19.10-   
Avg Mkt Cap Rs m28,083228 12,336.3%   
No. of employees `0006.0NA-   
Total wages/salary Rs m2,16769 3,126.6%   
Avg. sales/employee Rs Th1,817.0NM-  
Avg. wages/employee Rs Th359.0NM-  
Avg. net profit/employee Rs Th127.7NM-  
INCOME DATA
Net Sales Rs m10,968-322 -3,411.4%  
Other income Rs m40-35 -114.1%   
Total revenues Rs m11,007-356 -3,089.4%   
Gross profit Rs m1,565-694 -225.4%  
Depreciation Rs m6337 9,171.0%   
Interest Rs m62128 48.4%   
Profit before tax Rs m909-864 -105.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1393 4,623.3%   
Profit after tax Rs m771-867 -88.9%  
Gross profit margin %14.3215.9 6.6%  
Effective tax rate %15.3-0.3 -4,393.0%   
Net profit margin %7.0269.7 2.6%  
BALANCE SHEET DATA
Current assets Rs m5,7251,914 299.1%   
Current liabilities Rs m5,4542,795 195.1%   
Net working cap to sales %2.5274.2 0.9%  
Current ratio x1.00.7 153.3%  
Inventory Days Days620-  
Debtors Days Days72-1,467 -4.9%  
Net fixed assets Rs m5,30754 9,865.0%   
Share capital Rs m184133 138.8%   
"Free" reserves Rs m6,331-143 -4,424.3%   
Net worth Rs m6,5166 106,811.5%   
Long term debt Rs m1,3231 94,507.1%   
Total assets Rs m11,9702,817 424.9%  
Interest coverage x15.6-5.7 -272.8%   
Debt to equity ratio x0.20.2 88.5%  
Sales to assets ratio x0.9-0.1 -802.9%   
Return on assets %7.0-26.2 -26.5%  
Return on equity %11.8-14,214.8 -0.1%  
Return on capital %12.4-9,810.7 -0.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5070-   
Fx outflow Rs m1,1410-   
Net fx Rs m3,3660-   
CASH FLOW
From Operations Rs m886-404 -219.3%  
From Investments Rs m-1,706393 -434.0%  
From Financial Activity Rs m1,316-196 -670.2%  
Net Cashflow Rs m497-207 -239.4%  

Share Holding

Indian Promoters % 59.2 0.0 -  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 0.2 6,250.0%  
FIIs % 6.0 1.9 315.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 98.0 22.9%  
Shareholders   12,805 25,229 50.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   IIFL HOLDINGS  COMMEX TECHNOLOGY  INGERSOLL RAND  MIC ELECTRONICS  GEOJIT BNP PARIBAS  



Today's Market

Sensex Ends Near Record High; Realty Stocks Bleed(Closing)

After opening the day on a strong note, share markets in India witnessed volatility during the last hour of trading session. However, they managed to end the day on a positive note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Jan 18, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS